Incyte Q4 Revenue Soars 28% to $1.51B; Jakafi Drives $3.093B Sales
Incyte’s Q4 2025 revenue grew 28% year-over-year to $1.51 billion with full-year sales at $5.14 billion. Jakafi generated $3.093 billion annually while the core business excluding Jakafi jumped 53% in Q4, led by a 121% surge from Niktimvo and Monjuvi.
1. Fourth Quarter 2025 Financial Results
Incyte reported Q4 revenue of $1.51 billion, up 28% year-over-year, bringing full-year sales to $5.14 billion. This performance exceeded management’s internal targets and extends the company’s streak of double-digit revenue growth.
2. Flagship Product and Core Business Drivers
Jakafi remained the top revenue contributor with $3.093 billion in annual sales, while the core business excluding Jakafi delivered 53% Q4 growth. Key drivers included strengthened market penetration in dermatology through Opzelura and expanding indications for existing compounds.
3. Hematology and Oncology Franchise Performance
The hematology and oncology segment, anchored by Niktimvo and Monjuvi, saw a remarkable 121% revenue surge in Q4. This jump reflects successful label expansions and new partnership milestones that bolster long-term growth prospects.
4. 2026 Outlook and Pipeline Expansion
Management projects core business growth of over 30% in 2026, supported by regulatory submissions for Jakafi XR and povercinib. The company aims to launch 14 pivotal clinical trials by year-end, with investments in KRAS inhibitors and frontline DLBCL therapies driving future innovation.